Technology evaluation: ISIS-2503, Isis Pharmaceuticals

Current Opinion in Molecular Therapeutics

Volumn 3, Issue 6, 2001, Pages 589-594

  Morse, M A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ISIS 2503; NONSTEROID ANTIINFLAMMATORY AGENT; ONCOPROTEIN; PARACETAMOL; PROTEIN INHIBITOR; RAS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOTECHNOLOGY; BREAST TUMOR; CLINICAL TRIAL; COLON TUMOR; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG FORMULATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TISSUE LEVEL; ENCAPSULATION; FATIGUE; FEVER; GENE FUNCTION; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN CELL; LUNG TUMOR; MOUSE; NAUSEA; NEUTROPENIA; NONHUMAN; ONCOGENE C H RAS; PANCREAS TUMOR; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROTEIN EXPRESSION; SOLID TUMOR; THROMBOCYTOPENIA; URTICARIA;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HUMANS; MICE; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE;

ANIMALIA;

EID: 0035670054     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. "Making Drugs Out of Nucleosides and Nucleotides"
2. Antisense oligonucleotides demonstrate a dominant role of c-Ki-Ras proteins in regulating the proliferation of diploid human fibroblasts
3. Phosphorothioate antisense oligonucleotide inhibitors targeted to human c-Ha-Ras and c-Ki-Ras display potent antitumor activity
4. Isis receives thirteen patents covering antisense biology, chemistry and combinatorial chemistry; novel biology targets include ras, cell adhesion, CMV, HIV and flu
5. Isis begins phase I trials of third antisense anticancer drug; ISIS-2503 is a potent, selective inhibitor of Ha-Ras
6. Pharmacokinetics and disposition of ISIS 2503 encapsulated in Stealth-R liposomes administered by intravenous infusion to rhesus monkeys
7. Toxicity profile of ISIS 2503, a phosphorothioate oligodeoxynucleotide targeted to human H-Ras
8. Phase I trial of ISIS 2503, a 20-mer antisense phosphorothioate oligonucleotide against H-Ras, by 14-day continuous infusion in patients with advanced cancer
9. Antisense 98: Targeting the Molecular Basis of Disease
10. Antisense 98: Targeting The Molecular Basis of Disease
11. Oligonucleotide targeted against Ha-Ras in rastransgenic mouse tumor model
12. Isis begins phase II testing of third anticancer drug, ISIS-2503
13. Phase I and pharmacokinetic trial of ISIS 2503, a 20-mer antisense oligonucleotide against H-Ras, by 14-day continuous infusion (CIV) in patients with advanced cancer
14. Selective inhibition of mutant Ha-Ras mRNA expression by antisense oligonucleotides
15. A phase I trial of ISIS-2503, an antisense inhibitor of H-Ras, administered by a 24-hour (hr) weekly infusion to patients (pts) with advanced cancer
16. Isis presents data on cancer drugs at ASCO Conference - Highlights ISIS-3521 in non-small cell lung cancer
17. A phase I trial of ISIS 2503, an antisense inhibitor of H-Ras in combination with gemcitabine in patients with advanced cancer
18. OraSense joint venture announces pivotal first step in development of oral formulation of antisense drugs
19. A phase II trial of ISIS 2503, an antisense inhibitor of H-Ras, as first line therapy for advanced colorectal carcinoma
20. Pharmacokinetics and tissue disposition in monkeys of an antisense oligonucleotide inhibitor of Ha-Ras encapsulated in STEALTH liposomes
21. Phase II trial of ISIS 2503, an antisense inhibitor of H-Ras, in patients (Pts) with advanced pancreatic carcinoma (CA)
22. Multicenter phase II trial of an antisense inhibitor of H-Ras (ISIS-2503) in advanced non-small cell lung cancer (NSCLC)
23. Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-Ras mRNA in mouse and monkey
24. Drug development pipeline ISIS-2503
25. Phase II trials of ISIS-2503 in patients with advanced pancreatic cancer
26. Phase II trial of ISIS-2503 in patients with non-small cell lung cancer (NSCLC)